Dr Martens, a renowned boot manufacturer, anticipates facing significant financial losses due to increased US tariffs. The company, known for its iconic yellow-stitched boots, has shifted its manufacturing operations to Vietnam to avoid higher import duties resulting from the trade dispute initiated by US President Donald Trump.
Having previously relied on China for half of its production, Dr Martens has restructured its supply chain to mitigate the impact of US import tariffs. Despite the tariff challenges, the company remains confident in achieving its full-year profit forecasts of £53 million to £60 million, excluding the projected tariff impact.
The news of the tariff impact caused a sharp decline in Dr Martens’ stock price, dropping by over 10% in early trading. Nonetheless, the company plans to offset the additional tariff costs starting next year through stringent cost control measures, strategic product sourcing, and targeted adjustments to pricing policies in the US market.
CEO Ije Nwokorie expressed optimism about the brand’s resilience, highlighting a 33% increase in shoe volumes and successful launches of new products like the Zebzag Laceless boot and the 1460 Rain boot. Despite economic uncertainties and cautious consumer behavior, the company is confident in its strategies for the coming year.
While Dr Martens reported narrowed losses of £11 million in the first half of the fiscal year, down from £12.3 million in the previous year, sales saw a modest increase of 0.8% to £327.3 million. The investment director at broker AJ Bell, Russ Mould, acknowledged the company’s progress in its turnaround efforts but cautioned that the recovery process might be gradual rather than rapid.
Despite some positive signs in the half-year results, including improved product pricing and stronger performance in the Americas region, investor sentiment was subdued, leading to a decline in the company’s share price during early trading.